Raymond Faught, MD
Neurology · Birmingham, ALNPI 1497799134
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,786 of the $99,409 with a category attached, or 64.2%. 15 manufacturers reported payments, led by Neurelis, Inc. at 36.4% of the total. Reporting peaked in 2021 at $23,080 and has fallen 73.7% since, to $6,061 in 2025. Among neurology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $753.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$36K
- UCB SA$26K
- UCB, Inc.$8K
- Eisai Inc.$7K
- Trevena, Inc.$6K
- Supernus Pharmaceuticals, Inc.$5K
- plus $12K from 9 others
Across 11 payments — averaging $1755.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$11K
- SK Life Science, Inc.$4K
- UCB SA$2K
- Biogen$1K
What the payments were for
- Consulting fees$63,78664%
- Speaking & faculty fees$5,0085%
- Travel & lodging$25,14925%
- Food & beverage$5,4615%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 54 | $36,176 |
| UCB SA | 10 | $26,011 |
| UCB, Inc. | 18 | $7,516 |
| Eisai Inc. | 11 | $6,939 |
| Trevena, Inc. | 3 | $6,431 |
| Supernus Pharmaceuticals, Inc. | 9 | $4,666 |
| Eisai CO., LTD. | 4 | $3,284 |
| Azurity Pharmaceuticals, Inc. | 1 | $3,000 |
| SK Life Science, Inc. | 10 | $2,831 |
| Livanova USA, Inc. | 6 | $2,241 |
| Greenwich Biosciences, Inc. | 2 | $169 |
| Immedica Pharma US, Inc. | 1 | $61 |
| Sumitomo Pharma America, Inc. | 1 | $39 |
| AbbVie | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$34,651
- Briviact$15,165
- Fycompa$9,866
- Olinvyk$6,367
- OXTELLAR XR$4,463
- ZONISADE$3,000
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,378
- VNS - Sentiva$753
- XCOPRI$227
- Epidiolex$138
- Fintepla$123
How this compares
$99,409 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 11 | $229,052 |
| EpidiolexCannabidiol (Cbd) | 50 | $215,334 |
| XcopriCenobamate | 80 | $195,797 |
| BriviactBrivaracetam | 51 | $109,660 |
| AptiomEslicarbazepine Acetate | 60 | $104,198 |
| KeppraLevetiracetam | 33 | $70,353 |
| FycompaPerampanel | 35 | $40,346 |
| VimpatLacosamide | 25 | $36,614 |
| LamictalLamotrigine | 16 | $33,780 |
| Rufinamide | 26 | $29,220 |
| BanzelRufinamide | 14 | $28,003 |
| Lacosamide | 180 | $24,841 |
| Levetiracetam | 342 | $18,244 |
| ValtocoDiazepam | 18 | $14,043 |
| Depakote SprinkleDivalproex Sodium | 12 | $12,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Vimpat | $7,516 | $375,32587 claims |
| SK Life Science, Inc.Xcopri | $2,831 | $195,79780 claims |
| UCB SAKeppra | $26,011 | $70,35333 claims |
| Eisai Inc.Fycompa, Banzel | $6,939 | $68,34949 claims |
| Neurelis, Inc.Valtoco | $36,176 | $14,04318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
- Harrison WalkerBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.